First-pass extracted concept

co-stimulatory domain selection

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

Co-stimulatory domain selection is discussed as a key design issue in CAR engineering. The abstract specifically links it to persistence and optimal antitumor function.

Source 1DOI PubMed

Evidence Snippets

We also discuss the most pressing issues pertaining to the selection of co-stimulatory domains, with a focus on strategies aimed at promoting CAR-T cell persistence and optimal antitumor functionality.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2024MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1approach summarysupports2024Source 1DOI PubMed

The review summarizes adapter CAR systems, Boolean-logic gating, epitope editing, modulation of cell-intrinsic signaling pathways, safety switches, and co-stimulatory domain selection as main approaches to address CAR-T bottlenecks.

Claim 2design objectivesupports2024Source 1DOI PubMed

Co-stimulatory domain selection is discussed with a focus on promoting CAR-T cell persistence and optimal antitumor functionality.

Claim 3problem statementsupports2024Source 1DOI PubMed

Antigen escape variants, off-tumor destruction of healthy tissues expressing tumor-associated antigens, poor CAR-T cell persistence, and functional exhaustion are prominent hurdles limiting long-lasting remissions with tolerable adverse effects.

Claim 4problem statementsupports2024Source 1DOI PubMed

CAR-engineered T-cell therapy has achieved unprecedented response rates in some hematological malignancies but remains far from fulfilling its potential, especially in solid cancers.